KCM
TOVX icon

Knoll Capital Management’s Theriva Biologics TOVX Stock Holding History

Knoll Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-233
Closed -$1.55M – 19
2016
Q4 		$1.55M Sell
233
-194
-45% -$1.99M 2.72% 10
2016
Q3 		$6.61M Hold
427
– – 11.59% 3
2016
Q2 		$6.72M Hold
427
– – 2.18% 3
2016
Q1 		$8.81M Hold
427
– – 3.58% 2
2015
Q4 		$8.55M Hold
427
– – 3.17% 3
2015
Q3 		$8.48M Buy
427
+38
+10% +$935K 3.6% 3
2015
Q2 		$9.69M Hold
389
– – 3.12% 2
2015
Q1 		$7.45M Hold
389
– – 2.17% 3
2014
Q4 		$4.96M Buy
389
+234
+151% +$3.14M 1.95% 3
2014
Q3 		$2.39M Hold
155
– – 0.93% 6
2014
Q2 		$2.39M Hold
155
– – 1.07% 5
2014
Q1 		$3.5M Hold
155
– – 1.81% 4
2013
Q4 		$2.05M Buy
+155
New +$1.96M 1.03% 6

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Knoll Capital Management's TOVX Position: Q1 2017 in Review

Knoll Capital Management sold out of Theriva Biologics (TOVX) in Q1 2017, closing a stake of 233 shares — an estimated $1.55M sold.

Knoll Capital Management first reported a position in TOVX in Q4 2013 and held it in 13 quarters. The position peaked at $9.69M in Q2 2015. 74 funds tracked by Wall St. Rank hold TOVX as of Q1 2017.

  • Knoll Capital Management reported no remaining Theriva Biologics position as of Q1 2017 after selling out during the quarter.
  • Knoll Capital Management sold 233 Theriva Biologics shares in Q1 2017, an estimated $1.55M.
  • Knoll Capital Management first reported a position in Theriva Biologics in Q4 2013 and held it in 13 quarters.
  • Knoll Capital Management's Theriva Biologics position peaked at $9.69M in Q2 2015.
  • 74 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2017.

Based on Knoll Capital Management's 13F filing for Q1 2017, filed 15 May 2017.